When will the FDA approve retatrutide (LY3437943)
Leader sits at 91% across 5 bound outcomes, runner-up at 87%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.
Leader probability
Before Jan 1, 2029
Outcomes
5
winner-take-all
Runner-up
87¢
Before Jul 1, 2028
Spread
4pp
contested
24h volume
$245
thin orderbook
Closes
Jan 1, 2029
864 days
Venue
Kalshi
5 bound
30-day trend
Bracket family
How the bracket ladder is priced.
Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.
Cluster 1
When will the FDA approve retatrutide (LY3437943)
When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2027
KXFDARETATRUTIDE-RET-27JAN01
When will the FDA approve retatrutide (LY3437943)?: Before Jul 1, 2027
KXFDARETATRUTIDE-RET-27JUL01
When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2029
KXFDARETATRUTIDE-RET-29JAN01
When will the FDA approve retatrutide (LY3437943)?: Before Jul 1, 2028
KXFDARETATRUTIDE-RET-28JUL01
When will the FDA approve retatrutide (LY3437943)?: Before Jan 1, 2028
KXFDARETATRUTIDE-RET-28JAN01
Analysis
Markets currently assign a 92% probability that the FDA will approve retatrutide (Eli Lilly's obesity and diabetes drug) by January 1, 2029. This reflects confidence in eventual approval, though the contract chain shows material uncertainty about timing—traders see only a 16% chance of approval before January 2027, suggesting the review process extends beyond near-term. The probability is elevated by retatrutide's clinical trial data and Lilly's development track record with similar GLP-1 compounds, but remains below certainty because regulatory outcomes are never guaranteed. FDA action timelines depend on submission completeness, any safety signals during review, and the agency's current workload. The most immediate resolution point would be a formal FDA decision or any major clinical or manufacturing disclosure that affects approval likelihood.
- ›Retatrutide has shown clinical efficacy in Phase 3 trials, but approval hinges on FDA's safety and manufacturing review standards, which can extend timelines unpredictably
- ›The 65-cent contract for approval by July 2027 suggests a base-case timeline of 12–18 months from now, implying submission may already be in progress or imminent
- ›No scheduled FDA decision date is publicly confirmed; a breakthrough designation or priority review status would accelerate approval odds materially
- ›Manufacturing scale-up or supply-chain constraints could delay launch even after regulatory clearance
- ›Competitive GLP-1 drug approvals and label expansions may influence FDA prioritization but do not directly determine retatrutide's path
What moved the line
- Aug 19Before Jul 1, 2028↓23pp87→64¢ · Kalshi
- Aug 19Before Jan 1, 2029↓23pp91→68¢ · Kalshi
- Aug 20Before Jul 1, 2028↑16pp64→80¢ · Kalshi
- Aug 20Before Jan 1, 2029↑15pp68→83¢ · Kalshi
- Aug 14Before Jul 1, 2028↓10pp88→78¢ · Kalshi
Recently closed in general
- Will SpaceXAI release Grok 4.7 before Aug 21, 2026last 45% · 1d
- Will Trump nominate Stephen Hahn as FDA commissionerlast 49% · 1d
- Will James Fishback concede defeat in the the 2026 Florida gubernatorial race before Aug 20, 2026last 79% · 1d
- Will the US Strategic Petroleum Reserve level for the week ending July 3, 2026 be above 314Mlast 95% · 2d
- Will more than 6 House Democratic members lose their primary in 2026last 49% · 3d
These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.
More like this
Adjacent prediction questions.
In general
How we compute these odds
SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.
For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.
Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.
Last updated on this page: just now.